Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery
Authors
Kojiro Shimozuma
Patricia A. Ganz
Laura Petersen
Karim Hirji
Publication date
01-07-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006214830854

Other articles of this Issue 1/1999

Breast Cancer Research and Treatment 1/1999 Go to the issue

OriginalPaper

Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas

OriginalPaper

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

OriginalPaper

Rural breast cancer treatment: evidence from the Reaching Communities for Cancer Care (REACH) project

OriginalPaper

Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects

OriginalPaper

Schedule‐dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro

OriginalPaper

Suppression of parathyroid hormone‐related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits